DGXQuest Diagnostics
Quest Diagnostics works across the healthcare ecosystem to create a healthier world, one life at a time. 10-K, Item 1
- Employees
- 57,000
- Headquarters
- Secaucus, NJ
- CEO
- J. E. Davis
- Next results
- around Jan 11, 2027
3 paragraphs in Risk Factors of the 10-K filed Feb 26, 2026 with nothing like them in the 10-K filed Feb 20, 2025. Quoted exactly. Paragraphs that were only edited are under 10-K change.
Compared with the Risk Factors in the latest 10-K of the other 59 Health care companies: a paragraph with at least half its words the same at another company is called similar, and the companies are listed under it. A paragraph most of them have is marked boilerplate. No line means no other company has one like it. This counts text; it does not say how serious a risk is.
•the laws and regulations administered by foreign governments where we conduct clinical trials and operate outside of the United States;
Similar paragraph at 1 of 59 other Health care companies: HSICRead in the 10-K ↗
threatened by the U.S. government, and the responses to those actions from other countries, may result in adverse impacts to the global economic environment, including the global financial and trading markets, which could have a negative impact on our results of operations and financial condition. These actions could also negatively impact our supply chain costs or availability of products we need to operate our business. The ongoing uncertainty with the current state of global trade policy magnifies these risks.
Read in the 10-K ↗
(p) Challenges, including the associated competitive pressures, with properly managing the development, implementation, oversight and use of AI.
Read in the 10-K ↗
New in the latest 10-Q
7 paragraphs in the 10-Q filed Oct 23, 2026 with nothing like them in the 10-Q filed Jul 23, 2026 (at least half the words must differ; new numbers alone do not count). Quoted exactly, grouped by the item heading above them. This is text that changed, not a judgement of how serious it is.
10-Q
Adjustments to reconcile net income to net cash provided by operating activities:
Read in the 10-Q ↗
Employee payroll tax withholdings on stock issued under stock-based compensation plans (40) (44)
Read in the 10-Q ↗
Effect of exchange rate changes on cash and cash equivalents and restricted cash (2) 3
Read in the 10-Q ↗
The Company has entered into a definitive agreement to acquire select outreach lab assets from a leading health system and long-time Co-Lab Solutions customer in the Northeastern U.S. The transaction, which is expected to close later in 2026, remains subject to customary closing conditions.
Read in the 10-Q ↗
Three Months Ended September 30, 2026 2025 ────────────────────────────────────────────────────────────────────────────────────────────────────────────── (dollars in millions, except per share data) Net revenues $3,097 $2,816 DIS revenues $3,035 $2,755 Revenue per requisition change (4.2)% 0.8% Requisition volume change 14.5% 12.5% Organic requisition volume change 14.4% 3.9% DS revenues $62 $61 Operating income $479 $386 Net income attributable to Quest Diagnostics $312 $245 Diluted earnings per share $2.78 $2.16 Net cash provided by operating activities $611 $563 Capital expenditures $166 $144
Read in the 10-Q ↗
• pre-tax gains of $6 million, principally recorded in selling, general and administrative expenses, or $0.04 per diluted share, primarily related to insurance recoveries for certain legal matters; and
Read in the 10-Q ↗
Other information
Name Title Type of Trading Arrangement Security Action Date of Action Duration of Trading Arrangement Aggregate Number of Securities Covered Michael J. Deppe SVP, Corporate Controller and Chief Accounting Officer Rule 10b5-1 plan to sell Common Stock Adoption August 13, 2026 August 13, 2026 to August 13, 2027* Up to 11,776* Cathy Doherty EVP Rule 10b5-1 plan to sell Common Stock Adoption August 3, 2026 August 3, 2026 to April 30, 2027* Up to 34,252* Karthik Kuppusamy SVP, Clinical Solutions Rule 10b5-1 plan to sell Common Stock Adoption August 26, 2026 August 26, 2026 to April 30, 2027* Up to 1,000* Patrick Plewman SVP, Diagnostic Services Rule 10b5-1 plan to sell Common Stock Adoption August 11, 2026 August 11, 2026 to March 31, 2027* Up to 40,553* James E. Davis Chairman, Chief Executive Officer and President Rule 10b5-1 plan to sell Common Stock Adoption August 10, 2026 August 10, 2026 to December 31, 2027* Up to 172,095* ──────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
Read in the 10-Q ↗
The 10-Q's risk factors against the 10-K
Item 1A of the 10-Q filed Oct 23, 2026 against Item 1A of the 10-K filed Feb 26, 2026.
A 10-Q repeats only the risks that changed, so a 10-K paragraph that is missing from it is not counted as removed.
Added is a paragraph with nothing like it in the 10-K, Reworded a sentence that is in both with several words changed,
Quiet changes a sentence in both where one to four words changed and one is a hedge or a modal
(cut words struck through, new words highlighted and underlined).
Text on the page, not a score; each links to the filing at sec.gov.
What the 10-Q itself says about its risk factors:
Read in the 10-Q ↗
Item 1A. of our Annual Report on Form 10-K for the year ended December 31, 2025 includes a discussion of our risk factors. There have been no material changes in the risk factors described in that report.
1 paragraph in the 10-Q's Item 1A, and none of them adds, rewords or quietly edits a paragraph of the 10-K's.
Work on DGX in a spreadsheet:
Excel workbook (a sheet per section, ten years by column, charts, links to the filings) ·
CSV.
For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/DGX/export.csv") into a cell.